204 related articles for article (PubMed ID: 32497513)
1. Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa.
Pemmari T; Ivanova L; May U; Lingasamy P; Tobi A; Pasternack A; Prince S; Ritvos O; Makkapati S; Teesalu T; Cairo MS; Järvinen TAH; Liao Y
Mol Ther; 2020 Aug; 28(8):1833-1845. PubMed ID: 32497513
[TBL] [Abstract][Full Text] [Related]
2. Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa.
Cianfarani F; De Domenico E; Nyström A; Mastroeni S; Abeni D; Baldini E; Ulisse S; Uva P; Bruckner-Tuderman L; Zambruno G; Castiglia D; Odorisio T
Matrix Biol; 2019 Aug; 81():3-16. PubMed ID: 30528862
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP
J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene and n-Acetylcysteine Ameliorate TGF-Signalling in Fibroblasts from Patients with Recessive Dominant Epidermolysis Bullosa.
Aguado T; García M; García A; Ferrer-Mayorga G; Martínez-Santamaría L; Del Río M; Botella LM; Sánchez-Puelles JM
Cells; 2020 Sep; 9(9):. PubMed ID: 32947957
[TBL] [Abstract][Full Text] [Related]
5. Transtumoral targeting enabled by a novel neuropilin-binding peptide.
Roth L; Agemy L; Kotamraju VR; Braun G; Teesalu T; Sugahara KN; Hamzah J; Ruoslahti E
Oncogene; 2012 Aug; 31(33):3754-63. PubMed ID: 22179825
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-β antagonist and inhibitor of fibrosis.
Chacón-Solano E; León C; Carretero M; García M; Sánchez-Domínguez R; Quero F; Méndez-Jiménez E; Bonafont J; Ruiz-Mezcua B; Escámez MJ; Larcher F; Del Río M
Matrix Biol; 2022 Aug; 111():189-206. PubMed ID: 35779740
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
Baek DS; Kim JH; Kim YJ; Kim YS
Mol Pharm; 2018 Feb; 15(2):394-402. PubMed ID: 29232521
[TBL] [Abstract][Full Text] [Related]
8. Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa.
Gretzmeier C; Pin D; Kern JS; Chen M; Woodley DT; Bruckner-Tuderman L; de Souza MP; Nyström A
J Invest Dermatol; 2022 Apr; 142(4):1094-1102.e3. PubMed ID: 34606885
[TBL] [Abstract][Full Text] [Related]
9. Tumor-penetrating peptides.
Teesalu T; Sugahara KN; Ruoslahti E
Front Oncol; 2013; 3():216. PubMed ID: 23986882
[TBL] [Abstract][Full Text] [Related]
10. Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity.
Odorisio T; Di Salvio M; Orecchia A; Di Zenzo G; Piccinni E; Cianfarani F; Travaglione A; Uva P; Bellei B; Conti A; Zambruno G; Castiglia D
Hum Mol Genet; 2014 Aug; 23(15):3907-22. PubMed ID: 24599399
[TBL] [Abstract][Full Text] [Related]
11. Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series.
Pourani MR; Vahidnezhad H; Mansouri P; Youssefian L; Rakhshan A; Hajimoradi B; Abdollahimajd F; Uitto J
Dermatol Ther; 2022 Jul; 35(7):e15515. PubMed ID: 35420725
[TBL] [Abstract][Full Text] [Related]
12. Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts.
McBride JD; Rodriguez-Menocal L; Candanedo A; Guzman W; Garcia-Contreras M; Badiavas EV
Biochimie; 2018 Dec; 155():50-58. PubMed ID: 29653141
[TBL] [Abstract][Full Text] [Related]
13. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
Teesalu T; Sugahara KN; Kotamraju VR; Ruoslahti E
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16157-62. PubMed ID: 19805273
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-145-5p regulates fibrotic features of recessive dystrophic epidermolysis bullosa skin fibroblasts.
Condorelli AG; Logli E; Cianfarani F; Teson M; Diociaiuti A; El Hachem M; Zambruno G; Castiglia D; Odorisio T
Br J Dermatol; 2019 Nov; 181(5):1017-1027. PubMed ID: 30816994
[TBL] [Abstract][Full Text] [Related]
15. miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa.
Vanden Oever M; Muldoon D; Mathews W; McElmurry R; Tolar J
J Invest Dermatol; 2016 Oct; 136(10):2013-2021. PubMed ID: 27328306
[TBL] [Abstract][Full Text] [Related]
16. Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.
Nyström A; Thriene K; Mittapalli V; Kern JS; Kiritsi D; Dengjel J; Bruckner-Tuderman L
EMBO Mol Med; 2015 Sep; 7(9):1211-28. PubMed ID: 26194911
[TBL] [Abstract][Full Text] [Related]
17. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of chronicity signatures in fibroblasts isolated from recessive dystrophic epidermolysis bullosa chronic wound dressings under culture conditions.
De Gregorio C; Catalán E; Garrido G; Morandé P; Bennett JC; Muñoz C; Cofré G; Huang YL; Cuadra B; Murgas P; Calvo M; Altermatt F; Yubero MJ; Palisson F; South AP; Ezquer M; Fuentes I
Biol Res; 2023 May; 56(1):23. PubMed ID: 37161592
[TBL] [Abstract][Full Text] [Related]
19. [A case of recessive dystrophic epidermolysis bullosa associated with dwarfism with special reference to pathophysiological role of growth hormone].
Nakamura F; Rakugi H; Fukuo K; Nakamaru M; Masugi F; Onishi T; Ogihara T; Hashimoto K; Kozuka T; Yoshikawa K
Nihon Naibunpi Gakkai Zasshi; 1990 Feb; 66(2):94-100. PubMed ID: 2332081
[TBL] [Abstract][Full Text] [Related]
20. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
